Year
- 2026
- 2025
In the News
February 2026 – Healthcare Brew
Immuneering CEO shares his cancer drug development strategy
February 2026 – Pharmacy Times
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
February 2026 – CURE Today
New Combination Treatment Approach Studied in Pancreatic Cancer
February 2026 – Pharmacy Times
Improving Tolerability and Quality of Life in Pancreatic Cancer Treatment with Atebimetinib
February 2026 – Pharmaphorum
A cancer treatment modality that prioritises QoL, with Ben Zeskind
February 2026 – Pharmacy Times
Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes
January 2026 – Pharmacy Times
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
January 2026 – Targeted Oncology
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
January 2026 – Rare Cancer
Atebimetinib nearly doubles 1-year survival in pancreatic cancer study
January 2026 – Fierce Biotech
Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
January 2026 – FirstWord Pharma
Immuneering touts 'exceptional' 12-month OS for pancreatic cancer therapy
January 2026 – Endpoints News
Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show
December 2025 – Clinical Trials Arena
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
December 2025 – Rare Cancer News
Pancreatic cancer treatment atebimetinib set for Phase 3 trial
October 2025 – BioTuesdays
Immuneering outpacing cancer with a novel approach to improving overall survival
October 2025 – BiotechTV
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
October 2025 – Let’s Win Pancreatic Cancer
Early nine-month data from a clinical trial suggests a new promising first-line treatment option for patients newly diagnosed with pancreatic cancer.
October 2025 – Targeted Oncology
Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.
October 2025 – OncLive
Atebimetinib Plus Chemo Makes Case As Potential Frontline Option in Pancreatic Cancer
September 2025 – OncLive
First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer
September 2025 – Endpoints News
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year
September 2025 – The Scientist
A Slow and Steady Approach to Pancreatic Cancer Therapy
July 2025 – Pharmaceutical Executive
Changing the Ways We Treat Cancer
July 2025 – Forbes
A Slow And Steady Approach To Cancer Fighting
July 2025 – PharmaVoice
The MEK effect on cancer — a slow and steady approach to drug resistance
June 2025 – Targeted Oncology
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer
June 2025 – OncLive
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer
June 2025 – Fierce Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans
June 2025 – Cancer Network
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC
June 2025 – FirstWord Pharma
Immuneering touts strong survival in pancreatic cancer trial
June 2025 – Endpoints News
Immuneering says MEK pill beats standard of care in first-line pancreatic cancer